Community Practice Connections™: Optimizing Frontline Metastatic Pancreatic Cancer Treatment Through Best Practices in Treatment Selection and AE Management

Release Date: November 26, 2025

Expiration Date: November 26, 2026

Activity Overview

Selecting the optimal first-line treatment is critical for patients with metastatic pancreatic cancer, with a recent expansion of options for patients with genomically unselected disease. For patients who are able to receive second-line therapy, multiple targeted options should be considered for both KRAS-wildtype and KRAS-mutated pancreatic cancer.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from an Oncology Best Practice™: Optimizing Frontline Metastatic Pancreatic Cancer Treatment Through Best Practices in Treatment Selection and AE Management program. This unique and engaging activity is ideal for the community-based clinician. It focuses on first- and second-line therapies for treating metastatic pancreatic cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.

Target Audience

This educational program is directed toward academic and community oncologists, advanced practitioners, nurses, and other health care providers involved in the management of pancreatic cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Select first-line therapy for locally advanced or metastatic pancreatic cancer by evaluating biomarkers, clinical factors, and logistical aspects
• Develop an evidence-based plan for sequencing therapies in metastatic pancreatic cancer, considering age, performance status, and previous treatments
• Design a strategy to monitor for, prevent, and manage adverse effects from therapies for metastatic pancreatic cancer, ensuring maintenance of quality of life while continuing treatment

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.